Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-765 in chronic plaque psoriasis
NCT00205465Phase 2Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2004
- Modality
- Irreversible Covalent Inhibitors, Metabolically Activated Prodrugs
01
Overview
Phase 2, randomised, double-blind trial in plaque psoriasis comparing VX-765 with Placebo (2 arms). Primary endpoints: Incidence of adverse events, Abnormal laboratory values and 1 more. Started Dec 2004; status: completed.
02
Drugs
belnacasan
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00205465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00205465.